A Phase 1b/2a, Double-blinded, Placebo-controlled, Multiple Doses, 2 Step-up Study Evaluating the Safety, Tolerability, PK/PD and Efficacy of Systemic NS101 in Healthy Volunteers and SSNHL Patients
Latest Information Update: 16 Oct 2024
At a glance
- Drugs NS 101 Neuracle Science (Primary)
- Indications Sensorineural hearing loss
- Focus Adverse reactions
- Sponsors Neuracle Science
- 12 Feb 2024 New trial record